TSX: TLN       Thallion Pharmaceuticals Inc
Last Price Today's Change   Day's Range   Trading Volume
0.00   0.00 (0.00%)  0.00 - 0.00  0


Avg Volume (4 weeks):0
Average Price Target:-


No recent Headlines for this stock.

Business Background

Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its product candidates include: Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections and TLN-4601, a proprietary first-in-class small molecule with potential efficacy in multiple oncology indications. The Company also owns technology platform named DECIPHER, a genomics-based discovery platform technology. Its Shigamabs product consists of two monoclonal antibodies designed to bind specifically to Shiga toxin 1 and Shiga toxin 2 secreted by STEC. It has completed four Phase I clinical trials evaluating the safety of Shigamabs. Thallion owns approximately a 16% interest in Caprion Proteomics Inc. In August 2013, BELLUS Health Inc. acquired Thallion Pharmaceuticals Inc.

  Be the first to like this.


721  922  1225  1685 

Top 10 Active Counters
 ACB 3.00-0.59 
 ECA 5.50-0.26 
 APHA 5.03-0.62 
 PXI 0.065+0.005 
 TGOD 0.65-0.05 
 OGC 2.66+0.06 
 WEED 18.78-1.51 
 CPG 5.21-0.08 
 BTO 4.77+0.14 
 PEY 2.86-0.18 
Partners & Brokers